• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: O'Connor Rita M bought $50,122 worth of shares (13,700 units at $3.66), increasing direct ownership by 106% to 26,670 units

    3/16/22 8:33:47 AM ET
    $PLXP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PLXP alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    O'Connor Rita M

    (Last) (First) (Middle)
    9 FISHERS LANE
    SUITE E

    (Street)
    SPARTA NJ 07871

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    PLx Pharma Inc. [ PLXP ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    03/15/2022
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/15/2022 P 10,000 A $3.66 22,970 D
    Common Stock 03/15/2022 P 3,700 A $3.6546 26,670 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    /s/ Rita M. O'Connor 03/15/2022
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PLXP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PLXP

    DatePrice TargetRatingAnalyst
    12/7/2021$14.00Market Perform → Outperform
    Raymond James
    9/21/2021$29.00Buy
    BWS Financial
    More analyst ratings

    $PLXP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Giordano Natasha bought $14,977 worth of shares (4,100 units at $3.65), increasing direct ownership by 378% to 5,186 units

      4 - PLx Pharma Inc. (0001497504) (Issuer)

      3/16/22 8:35:24 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: O'Connor Rita M bought $50,122 worth of shares (13,700 units at $3.66), increasing direct ownership by 106% to 26,670 units

      4 - PLx Pharma Inc. (0001497504) (Issuer)

      3/16/22 8:33:47 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Valentino Michael J

      4 - PLx Pharma Inc. (0001497504) (Issuer)

      2/24/22 8:18:05 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PLXP
    Financials

    Live finance-specific insights

    See more

    $PLXP
    Leadership Updates

    Live Leadership Updates

    See more
    • PLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business Update

      - Significant Reduction in Operating Expenses - Strategic Alternatives Process Ongoing Total Net Sales of $0.4 Million, Including $0.3 Million of Unfavorable Adjustments for Additional Trade Allowances and Incremental Sales Returns Reserves in Q3 2022Total Operating Expenses Significantly Lower by $2.8 Million, or 22%, in Q3 2022 vs. Q3 2021; $4.4 Million or 31% Lower Sequentially vs. Q2 2022GAAP Net Loss of ($0.30) Per Diluted Share in Q3 2022; Adjusted Non-GAAP Net Loss Per Diluted Share of ($0.37)Cash & Cash Equivalent Balance of $25.8 Million as of September 30, 2022 SPARTA, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a c

      11/10/22 5:00:00 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PLx Pharma Inc. to Report Third Quarter 2022 Financial Results on November 11, 2022, and Provide Business Update

      SPARTA, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company") is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as "VAZALORE®"), today announced that it will release its third quarter 2022 financial results before the open of the U.S. financial markets on Friday, November 11, 2022. Followi

      10/26/22 9:00:00 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PLx Pharma Inc. Reports Second Quarter 2022 Results and Provides Business Update

      - Initiates Evaluation of Strategic Alternatives to Enhance Stockholder Value - Reports Positive Results of VAZALORE® 81 mg Patient Experience Survey - Streamlines Sales & Marketing Plan Total Net Sales of $0.5 Million, Including $0.4 Million of Unfavorable Adjustments for Additional Trade Allowances and Incremental Sales Returns Reserves in Second Quarter of 2022Total Operating Expenses Were Lower by $4.9 Million in Second Quarter of 2022 vs. Q1 2022GAAP Net Loss of ($0.43) Per Diluted Share in Second Quarter of 2022; Adjusted Non-GAAP Net Loss Per Diluted Share of ($0.52)Cash & Cash Equivalent Balance of $35.7 Million as of June 30, 2022 SPARTA, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) -

      8/12/22 6:50:00 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PLx Pharma Inc. Appoints Janet Barth to Newly Created Role of Vice President, Investor Relations & Corporate Communications

      SPARTA, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg liquid-filled aspirin capsules (referred to together as "VAZALORE"), announced today the appointment of Janet M. Barth as Vice President, Investor Relations & Corporate Communications, effective immediately. As a member of the Exec

      1/19/22 6:50:00 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PLXP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE® and Substantially All of its Assets

      SPARTA, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ and VAZALORE®, an FDA-approved liquid-filled aspirin capsule, available in 81 mg and 325 mg doses. The Company today announced that it entered into a stalking horse asset purchase agreement (the "APA") with PLx Acquisition Company, LLC, a wholly-owned subsidiary of Greenwood Brands, LLC ("Buyer"), to acquire substantially all of the Company's assets (the "Sale"). The Company intends to file voluntary petitions for relief under Chapter 11 of Title 11 of the

      4/12/23 5:24:09 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PLx Pharma Inc. Receives Nasdaq Delisting Notice

      SPARTA, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company had previously announced that on October 3, 2022, it was notified by the Listing Qualifications Department (the "Listing Qualifications Department") of the Nasdaq Stock Market LLC ("Nasdaq") that the Listing Qualifications Department has determined to delist the Company's securities from Na

      4/11/23 4:28:31 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business Update

      - Significant Reduction in Operating Expenses - Strategic Alternatives Process Ongoing Total Net Sales of $0.4 Million, Including $0.3 Million of Unfavorable Adjustments for Additional Trade Allowances and Incremental Sales Returns Reserves in Q3 2022Total Operating Expenses Significantly Lower by $2.8 Million, or 22%, in Q3 2022 vs. Q3 2021; $4.4 Million or 31% Lower Sequentially vs. Q2 2022GAAP Net Loss of ($0.30) Per Diluted Share in Q3 2022; Adjusted Non-GAAP Net Loss Per Diluted Share of ($0.37)Cash & Cash Equivalent Balance of $25.8 Million as of September 30, 2022 SPARTA, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a c

      11/10/22 5:00:00 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PLXP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • PLx Pharma upgraded by Raymond James with a new price target

      Raymond James upgraded PLx Pharma from Market Perform to Outperform and set a new price target of $14.00

      12/7/21 5:38:25 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BWS Financial initiated coverage on PLx Pharma with a new price target

      BWS Financial initiated coverage of PLx Pharma with a rating of Buy and set a new price target of $29.00

      9/21/21 8:29:27 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on PLx Pharma with a new price target

      Oppenheimer initiated coverage of PLx Pharma with a rating of Outperform and set a new price target of $20.00

      4/9/21 7:21:28 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PLXP
    SEC Filings

    See more
    • SEC Form 15-12G filed by PLx Pharma Inc.

      15-12G - PLx Pharma Winddown Corp. (0001497504) (Filer)

      10/18/23 4:01:55 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PLx Pharma Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Other Events, Financial Statements and Exhibits

      8-K - PLx Pharma Winddown Corp. (0001497504) (Filer)

      9/20/23 4:39:55 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PLx Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - PLx Pharma Winddown Corp. (0001497504) (Filer)

      8/22/23 5:24:50 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PLXP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by PLx Pharma Inc.

      SC 13G - PLx Pharma Inc. (0001497504) (Subject)

      4/6/23 9:15:24 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by PLx Pharma Inc. (Amendment)

      SC 13G/A - PLx Pharma Inc. (0001497504) (Subject)

      2/14/23 1:38:55 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by PLx Pharma Inc. (Amendment)

      SC 13G/A - PLx Pharma Inc. (0001497504) (Subject)

      2/16/22 6:15:38 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care